{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication&page=12",
    "query": {
      "intervention": "Medication",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 28800,
    "total_pages": 2880,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T13:59:44.129Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00785486",
      "title": "Drug-Drug Interaction Study of Qualaquin and Midazolam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Midazolam Alone",
          "type": "DRUG"
        },
        {
          "name": "Qualaquin (quinine) alone steady state",
          "type": "DRUG"
        },
        {
          "name": "Midazolam and Qualaquin at steady state",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mutual Pharmaceutical Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2007-03",
      "completion_date": "2007-03",
      "has_results": true,
      "last_update_posted_date": "2012-08-31",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00785486"
    },
    {
      "nct_id": "NCT02661373",
      "title": "First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "SJ733",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-03-01",
      "completion_date": "2018-03-09",
      "has_results": false,
      "last_update_posted_date": "2019-01-02",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661373"
    },
    {
      "nct_id": "NCT03509883",
      "title": "Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Drug: Apixaban sprinkle capsules",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Apixaban tablets followed by apixaban sprinkle capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 94,
      "start_date": "2018-04-26",
      "completion_date": "2018-06-15",
      "has_results": true,
      "last_update_posted_date": "2020-01-23",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03509883"
    },
    {
      "nct_id": "NCT01783054",
      "title": "Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma Pancreas"
      ],
      "interventions": [
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Genetic Expression",
          "type": "GENETIC"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2012-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-03-08",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01783054"
    },
    {
      "nct_id": "NCT02865005",
      "title": "Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone 5.0% Gel (SEEGPharm)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Dapsone 5.0% Gel (Allergan)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seegpharm S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 2361,
      "start_date": "2016-02",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-20",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 35,
      "location_summary": "Encino, California • Fullerton, California • La Mesa, California + 29 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02865005"
    },
    {
      "nct_id": "NCT02782741",
      "title": "Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glycogen Storage Disease Type II;Pompe's Disease"
      ],
      "interventions": [
        {
          "name": "Avalglucosidase alfa (GZ402666)",
          "type": "DRUG"
        },
        {
          "name": "Alglucosidase alfa (GZ419829)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2016-11-02",
      "completion_date": "2023-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02782741"
    },
    {
      "nct_id": "NCT02008994",
      "title": "Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Genomic and Proteomic Profiling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sanford Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2013-09",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02008994"
    },
    {
      "nct_id": "NCT04262466",
      "title": "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Select Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Brenetafusp",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and monoclonal antibodies and chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and tebentafusp",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and kinase inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunocore Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2020-02-25",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04262466"
    },
    {
      "nct_id": "NCT01659866",
      "title": "Antibiotic Prophylaxis for Transrectal Prostate Biopsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infection"
      ],
      "interventions": [
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "trimethoprim-sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "cefuroxime",
          "type": "DRUG"
        },
        {
          "name": "ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "gentamicin",
          "type": "DRUG"
        },
        {
          "name": "amikacin",
          "type": "DRUG"
        },
        {
          "name": "aztreonam",
          "type": "DRUG"
        },
        {
          "name": "imipenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "90 Years",
        "sex": "MALE",
        "summary": "30 Years to 90 Years · Male only"
      },
      "enrollment_count": 563,
      "start_date": "2012-08",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01659866"
    },
    {
      "nct_id": "NCT00346151",
      "title": "Belatacept to Prevent Organ Rejection in Kidney Transplant Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2006-12",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-22T13:59:44.129Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Atlanta, Georgia",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346151"
    }
  ]
}